Middle East and Africa Radiopharmaceuticals Market Dynamics and Trends by 2028
Historic Data: 2019-2020 | Base Year: 2021 | Forecast Period: 2022-2028Middle East and Africa Radiopharmaceuticals Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine), Application (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Imaging Centers, Academic and Research Centers, and Others)
- Report Date : Nov 2021
- Report Code : TIPRE00025880
- Category : Life Sciences
- Status : Published
- Available Report Formats :
- No. of Pages : 142
The MEA radiopharmaceuticals market is expected to grow from US$ 381.20 million in 2021 to US$ 639.78 million by 2028; it is estimated to grow at a CAGR of 7.7% from 2021 to 2028.
The UAE, Saudi Arabia, and South Africa are major economies in MEA. Burgeoning usage of nuclear medicines for personalized treatment is expected to fuel the market growth. In personalized care, treatment is individualized based on specific biochemical markers detected in patients as well as on the characteristics of their disease condition. Imaging techniques identify patients for particular therapies and optimize patient response to treatment while minimizing side effects. Precision medicine involves the use of an individual’s genomic information to offer them targeted treatment. In recent years, scientists are focusing on pioneering neurogenetics to introduce better therapies and treatment for brain and related disorders. Nuclear medicine is gaining pace gradually, and targeted radionuclide therapy provides efficacious treatment modalities against cancer. The latest innovations involve using radionuclides, new or improved multimodality imaging devices, and several recently marketed radiopharmaceuticals in all medical applications, particularly cardiology, neurology, and oncology. Current developments in self-shielded cyclotrons, video-monitored hot cell designs, improved targets, and automated PET radiopharmaceutical synthesis modules, based on computer-controlled graphic user interphase (GUI), have revolutionized the PET molecular imaging technology for basic biomedical research to accomplish evidence-based personalized medicine. Further advancements in novel PET radiopharmaceutical utilizing automated microfluidic synthesis modules and multifunctional nanoparticles, are likely to improve biomarker discovery, internal dosimetry, immunotherapy, pharmacokinetics, and stem cell tracking in regenerative medicine. The peptide receptor radionuclide therapy (PRRT) is at the forefront of new personalized medicines. The somatostatin analogs used in this technique, which bind selectively to cellular receptors on the neuroendocrine tumor cells, carry a gallium radionuclide that simultaneously emits radiation that kills tumors and makes the analogs visible as well as quantifiable with PET. The end effect of successful and measurable treatment is decreased tumor size and reduced symptoms, along with a halt in tumor progression in many patients. Thus, the use of nuclear medicines in personalized medicine is emerging as a prime future trend in the MEA radiopharmaceuticals market.
In case of COVID-19, MEA is highly affected especially South Africa. Countries in the Middle East have also widely affected the socio-economic condition by the COVID–19 pandemic. However, the countries have wisely reacted to the COVID–19 pandemic to avoid the spread of infection. Like other regions, lockdown and social distancing were imposed, impairing these trends hindering access to work, regular income, payments, fairs, schools, and healthcare. Therefore, it is expected that the countries have undergone huge losses and are still trying to recover them. The lockdown has widely affected the non-emergency medical services in the region, affecting the medical devices. Countries like Saudi Arabia and UAE are emerging as healthcare destinations in the regions. However, they are dependent on the countries for the resources. The availability of vaccines and other healthcare facilities in the developing countries in the region is expected to provide scope for the market few years. The COVID-19 pandemic has helped the above-mentioned countries enhance their capacity and showcase their abilities for healthcare services. In Saudi Arabia the number of visits for common neurological complaints decreased by 24 percent. In comparison to pre-pandemic, throughout the pandemic period. The most notable example is brain CT scans, which increased by 11.3 percent during the epidemic period. One of the main causes for the decrease in emergency department visits is the fear of catching COVID-19 infection just by visiting hospitals. These factors are likely to have negative impact on the market growth.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA radiopharmaceuticals market. The MEA radiopharmaceuticals market is expected to grow at a good CAGR during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
MEA Radiopharmaceuticals Market Segmentation
MEA Radiopharmaceuticals Market – By Type
- Diagnostic Nuclear Medicine
- SPECT
- PET
- Therapeutic Nuclear Medicine
- Alpha Emitters
- Beta Emitters
- Brachytherapy Isotopes
MEA Radiopharmaceuticals Market – By Application
- Oncology
- Cardiology
- Neurology
- Others
MEA Radiopharmaceuticals Market – By End User
- Hospitals
- Imaging Centers
- Academic and Research Centers
- Others
MEA Radiopharmaceuticals Market, by Country
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
MEA Radiopharmaceuticals Market -Companies Mentioned
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBAŞI MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Nordion
- NTP RADIOISOTOPES
Middle East and Africa Radiopharmaceuticals Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 381.20 Million |
| Market Size by 2028 | US$ 639.78 Million |
| Global CAGR (2021 - 2028) | 7.7% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | Middle East and Africa
|
| Market leaders and key company profiles |
Market Research & Consulting
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials
I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.
- Advanced Accelerator Applications
- Bayer AG
- Bracco Imaging S.p.A
- Cardinal Health Inc
- Curium
- ECZACIBA?I MONROL NUCLEAR PRODUCTS CO.
- GENERAL ELECTRIC
- Nordion
- NTP RADIOISOTOPES
Get Free Sample For